ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. Stock
With only a change of €0.001 (0.070%) the ProQR Therapeutics N.V. price is nearly unchanged from yesterday.
ProQR Therapeutics N.V. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 6 € there is potential for a 313.79% increase which would mean more than doubling the current price of 1.45 € for ProQR Therapeutics N.V..
Our community identified positive and negative aspects for ProQR Therapeutics N.V. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the ProQR Therapeutics N.V. stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | 0.070% | -4.164% | 18.755% | -6.270% | -13.742% | -45.815% | -64.806% |
| Pharming Group | -2.700% | -3.306% | -3.306% | 55.529% | -9.937% | 17.000% | 14.298% |
| Formycon AG | -1.660% | -6.173% | -20.335% | -29.236% | -25.636% | -73.088% | -68.543% |
| Heron Therapeutics Inc. | -5.000% | -7.083% | -20.452% | -64.977% | -30.521% | -65.330% | -94.528% |
Comments
ProQR Therapeutics (PRQR) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $9.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat